Low-dose inhaled versus standard dose oral form of anti-tubercular drugs: Concentrations in bronchial epithelial lining fluid, alveolar macrophage and serum

Journal of Postgraduate Medicine

Volumn 54, Issue 3, 2008, Pages 245-246

  Katiyar, S ^a   Bihari, S ^a   Prakash, S ^a  

^a GSVM MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; BRONCHUS MUCOSA; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG TISSUE LEVEL; DRY POWDER; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN EXPERIMENT; INFORMED CONSENT; LETTER; LOW DRUG DOSE; LUNG ALVEOLUS MACROPHAGE; NORMAL HUMAN; POWDER INHALER; TABLET FORMULATION;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADULT; ANTITUBERCULAR AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIUM; FEMALE; HUMANS; ISONIAZID; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; MUCOUS MEMBRANE; PYRAZINAMIDE; RIFAMPIN; YOUNG ADULT;

EID: 47549095695     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: 10.4103/0022-3859.41823     Document Type: Letter

References (2)

1. Pandey R, Khuller GK. Antitubercular inhaled therapy: Opportunities, progress and challenges. J Antimicrob Chemother 2005;55:430-5.
2. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995;50:105-10.